Universal Beteiligungs und Servicegesellschaft mbH Cuts Stock Position in TG Therapeutics, Inc. $TGTX

Universal Beteiligungs und Servicegesellschaft mbH decreased its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 3.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 192,323 shares of the biopharmaceutical company’s stock after selling 6,727 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.12% of TG Therapeutics worth $6,922,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. CWM LLC lifted its holdings in TG Therapeutics by 16.2% during the first quarter. CWM LLC now owns 2,085 shares of the biopharmaceutical company’s stock valued at $82,000 after purchasing an additional 290 shares in the last quarter. Victory Capital Management Inc. raised its position in shares of TG Therapeutics by 70.4% during the 1st quarter. Victory Capital Management Inc. now owns 92,081 shares of the biopharmaceutical company’s stock worth $3,631,000 after purchasing an additional 38,047 shares during the last quarter. Kestra Private Wealth Services LLC purchased a new position in TG Therapeutics in the 1st quarter valued at about $221,000. Choreo LLC lifted its stake in TG Therapeutics by 7.6% in the 1st quarter. Choreo LLC now owns 8,547 shares of the biopharmaceutical company’s stock valued at $337,000 after buying an additional 602 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new stake in TG Therapeutics in the 1st quarter worth about $668,000. Hedge funds and other institutional investors own 58.58% of the company’s stock.

Insiders Place Their Bets

In other news, Director Sagar Lonial sold 20,852 shares of the stock in a transaction that occurred on Thursday, September 11th. The shares were sold at an average price of $32.24, for a total value of $672,268.48. Following the completion of the sale, the director owned 94,061 shares of the company’s stock, valued at $3,032,526.64. This represents a 18.15% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 10.64% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

TGTX has been the subject of a number of research analyst reports. Weiss Ratings reissued a “hold (c+)” rating on shares of TG Therapeutics in a report on Wednesday. HC Wainwright assumed coverage on TG Therapeutics in a research report on Monday, October 6th. They set a “buy” rating and a $60.00 price target for the company. B. Riley upgraded TG Therapeutics to a “strong-buy” rating in a report on Tuesday, November 4th. JPMorgan Chase & Co. lifted their target price on shares of TG Therapeutics from $46.00 to $49.00 and gave the stock an “overweight” rating in a research note on Monday, November 3rd. Finally, Wall Street Zen upgraded shares of TG Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, TG Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $50.25.

TG Therapeutics Stock Up 0.4%

Shares of NASDAQ:TGTX opened at $30.45 on Friday. TG Therapeutics, Inc. has a 52-week low of $25.28 and a 52-week high of $46.48. The stock has a market cap of $4.83 billion, a P/E ratio of 82.30 and a beta of 1.96. The business has a fifty day moving average of $33.79 and a two-hundred day moving average of $33.99. The company has a quick ratio of 2.96, a current ratio of 3.86 and a debt-to-equity ratio of 0.89.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $2.43 earnings per share for the quarter, beating the consensus estimate of $0.24 by $2.19. TG Therapeutics had a net margin of 13.31% and a return on equity of 26.05%. The firm had revenue of $161.71 million for the quarter, compared to analysts’ expectations of $152.12 million. During the same quarter in the previous year, the company posted $0.02 EPS. The company’s revenue was up 92.7% compared to the same quarter last year. TG Therapeutics has set its FY 2025 guidance at EPS. On average, research analysts expect that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.